FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer

FDA Approvals, New treatment options for ovarian cancer.

Nuvox Pharma announces that the FDA has allowed an Investigational New Drug (IND) application to initiate a Phase II clinical trial for its oxygen therapeutic, NVX-108, in patients with the hypoxic solid brain tumor, glioblastoma multiforme (GBM). NVX-108 is an injectable drug that travels through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where it passively delivers the oxygen. It is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation therapy and chemotherapy.

The clinical trial’s principal investigator, Baldassarre Stea, MD, PhD, said, “Tumor hypoxia is known to be a problem in many tumor types, including GBM. Hypoxic tumors are resistant to radiation therapy and certain kinds of chemotherapy. By increasing tumor oxygen levels, NVX-108 is designed to improve the effectiveness of these therapies in order to kill cancer cells more effectively and increase patient survival. Clinical trials are needed to see if NVX-108 can become approved by regulators.”

NuvOx Pharma is a clinical stage pharmaceutical company that is developing a platform of oxygen therapeutics. In addition to the above oncology trial, the company also has a product in a Phase Ib/II clinical trial in acute ischemic stroke, and has an IND allowed for a Phase Ib clinical trial for sickle cell crisis.

For further information, please see www.nuvoxpharma.com or contact John McGonigle at jmcgonigle@nuvoxpharma.com.

 

Be the first to comment on "FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain Cancer"

Leave a Reply

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.